Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer

Sobstyl, Małgorzata; Niedźwiedzka-Rystwej, Paulina; Hrynkiewicz, Rafał; Bębnowska, Dominika; Korona-Głowniak, Izabela; Pasiarski, Marcin; Sosnowska‐Pasiarska, Barbara; Smok-Kalwat, Jolanta; Góźdż, Stanisław; Sobstyl, Anna; Polkowski, Wojciech; Roliński, Jacek; Grywalska, Ewelina

doi:10.3390/biom11081205

Cited by 7 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After text mining, a total of 12 genes were found to be associated with EOC which are coexpression with SLFN5. GO pathway analyses showed that the translational initiation pathway (GO:0006413) was the most significant pathway involved with FAU,RBM4,POLR2G,NLRP3,TLR1,TLR6,TLR2,MRPL33, MRPS16, MRPL12,MRPL11,MRPL21,CHCHD1,TLR2 and MRPS16 have been reported to be associated with the development of ovarian cancer in previous studies [ 34 ]. Among the Mitochondrial translational initiation pathway, the high expression of SLFN5 was closely related with poor survival of patients with ovarian cancer and SLFN5 was prominently overexpressed in the three ovarian cancer cell lines, making it a candidate gene for further analysis.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

Deng

Zhang

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer is a disease with increasing incidence worldwide, and there is an urgent need for chemotherapy and biological targeted therapy. Epithelial-mesenchymal transformation (EMT) is an important initiation stage for tumor cells to acquire the ability to invade and metastasize. A growing number of findings suggest that human Schlafen family member 5(SLFN5) plays a key role in malignancy. However, the role of SLFN5 in ovarian cancer cells has not been fully elucidated. Samples were collected from patients with ovarian cancer diagnosed in Hangzhou First People's Hospital, and the expression of SLFN5 was detected by fluorescence quantitative PCR. The relationship between SLFN5 expression and the progression and malignancy of ovarian cancer was analyzed by using the expression profile data from the Cancer Genome Atlas (TCGA) database. The mRNA expression levels of SLFN5 related upstream and downstream signaling pathways were studied by fluorescence quantitative PCR. Silencing SLFN5 was performed by siRNA transfection. The expression of SLFN5 and transfer-related proteins was examined by Western blot. Transwell and wound healing experiments investigated the migration and invasion ability of ovarian cancer cells. TCGA database analysis results showed that in the population with high SLFN5 expression, compared with the group with low SLFN5 expression, OS was worse (P = 0.011). SLFN5 silencing had a significant inhibitory effect on EMT and invasion movement of ovarian cancer cells. RT-PCR method was used to detect the mRNA changes of SLFN5 in ovarian cancer tissue and adjacent tissue. It was found that the expression of SLFN5 in ovarian cancer tissue was increased, with a significant difference (P < 0.05). Together, these results suggest that SLFN5 may play a synergistic role in tumorigenesis and development of ovarian cancer cells, providing a potential target for future drug development for the treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

Deng

Zhang

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…27 Although TLR2 is one of the most studied members of the TLR family, there are still no conclusive studies on the effects of TLR2 expression in ovarian cancer. 16 The present study shows that TLR2 is downregulated in EOC patients compared with healthy controls. In contrast, Zhang et al 28 and Sobstyl 16 have documented significantly increased TLR2 expression in women with ovarian cancer.…”

Section: Discussionsupporting

confidence: 52%

“…However, in a recent study that highlighted BTLA and CD27 as unfavorable prognostic factors for ovarian cancer, only 5 ICs were considered for ovarian cancer. 16 In the present study, 16 ICs were evaluated as theranostic biomarkers for EOC.…”

Section: Discussionmentioning

confidence: 98%

Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer

Habel

Ahmed

et al. 2023

Int J Biol Markers

View full text Add to dashboard Cite

Background Epithelial ovarian cancer (EOC) is the leading cause of death associated with gynecologic tumors. EOC is asymptomatic in early stages, so most patients are not diagnosed until late stages, highlighting the need to develop new diagnostic biomarkers. Mediators of the tumoral microenvironment may influence EOC progression and resistance to treatment. Aim To analyze immune checkpoints to evaluate them as theranostic biomarkers for EOC. Patients and methods Serum levels of 16 immune checkpoints were determined in EOC patients and healthy controls using the MILLIPLEX MAP® Human Immuno-Oncology Checkpoint Protein Magnetic Bead Panel. Results Seven receptors: BTLA, CD40, CD80/B7-1, GITRL, LAG-3, TIM-3, TLR-2 are differentially expressed between EOC and healthy controls. Serum levels of immune checkpoints in EOC patients are positively significantly correlated with levels of their ligands, with a higher significant correlation between CD80 and CTLA4 than between CD28 and CD80. Four receptors, CD40, HVEM, PD-1, and PD-L1, are positively associated with the development of resistance to Taxol-platinum-based chemotherapy. All of them have an acceptable area under the curve (>0.7). Conclusion This study has yielded a first panel of seven immune checkpoints (BTLA, CD40, CD80/B7-1, GITRL, LAG-3, TIM-3, TLR-2) associated with a higher risk of EOC and a second panel of four immune checkpoints (CD40, HVEM, PD-1, PD-L1) that may help physicians to identify EOC patients who are at high risk of developing resistance to EOC chemotherapy.

show abstract

“…In our study,122 overlapping genes were identi ed as candidate genes related to EOC progression.After text mining, a total of 12 genes were found to be associated with EOC which are coexpression with SLFN5.GO pathway analyses showed that the translational initiation pathway(GO:0006413)was the most signi cant pathway involved with FAU,RBM4,POLR2G,NLRP3,TLR1,TLR6,TLR2,MRPL33, MRPS16, MRPL12,MRPL11,MRPL21,CHCHD1,TLR2 and MRPS16 have been reported to be associated with the development of ovarian cancer in previous studies [34] .Among the Mitochondrial translational initiation pathway,the high expression of SLFN5 was closely related with poor survival of patients with ovarian cancer and SLFN5 was prominently overexpressed in the three ovarian cancer cell lines, making it a candidate gene for further analysis.To our knowledge,this is the rst study to explore the clinical signi cance of SLFN5 in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Human Schlafen 5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

deng¹,

Zhang²,

Shang³

2022

Preprint

View full text Add to dashboard Cite

Ovarian cancer is a disease with increasing incidence worldwide, and there is an urgent need for chemotherapy and biological targeted therapy.Epithelial-mesenchymal transformation (EMT) is an important initiation stage for tumor cells to acquire the ability to invade and metastasize.A growing number of findings suggest that human Schlafen family member 5(SLFN5) plays a key role in malignancy.However, the role of SLFN5 in ovarian cancer cells has not been fully elucidated.Samples were collected from patients with ovarian cancer diagnosed in Hangzhou First People's Hospital, and the expression of SLFN5 was detected by fluorescence quantitative PCR.The relationship between SLFN5 expression and the progression and malignancy of ovarian cancer was analyzed by using the expression profile data from the Cancer Genome Atlas (TCGA) database.The mRNA expression levels of SLFN5 related upstream and downstream signaling pathways were studied by fluorescence quantitative PCR.Silencing SLFN5 was performed by siRNA transfection.The expression of SLFN5 and transfer-related proteins was examined by Western blot.Transwell and wound healing experiments investigated the migration and invasion ability of ovarian cancer cells. TCGA database analysis results showed that in the population with high SLFN5 expression,compared with the group with low SLFN5 expression,OS was worse (P = 0.011).SLFN5 silencing had a significant inhibitory effect on EMT and invasion movement of ovarian cancer cells.RT-PCR method was used to detect the mRNA changes of SLFN5 in ovarian cancer tissue and adjacent tissue. It was found that the expression of SLFN5 in ovarian cancer tissue was increased, with a significant difference (P < 0.05). Together, these results suggest that SLFN5 may play a synergistic role in tumorigenesis and development of ovarian cancer cells, providing a potential target for future drug development for the treatment of ovarian cancer.

show abstract

Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer

Cited by 7 publications

References 33 publications

RETRACTED ARTICLE: SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

RETRACTED ARTICLE: SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer

Human Schlafen 5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer

Contact Info

Product

Resources

About